NLRP3 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “NLRP3 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in NLRP3 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
NLRP3 protein inhibitors: Overview
The NLRP3 inflammasome regulates the release of pro-inflammatory cytokines in response to “danger signals,” including the presence of foreign or endogenous molecules that signal infection, tissue damage or metabolic imbalances. Chronic inflammation driven by improper activation of the NLRP3 inflammasome has been implicated in a wide array of diseases, including fibrotic, autoinflammatory and neurodegenerative diseases, as well as certain cancers. Small molecules that selectively inhibit NLRP3 have well-understood potential to address improper activation and treat chronic inflammation at the source, without broadly suppressing the immune system.
Report Highlights
This segment of the NLRP3 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NLRP3 protein inhibitors Emerging Drugs
Further product details are provided in the report……..
NLRP3 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NLRP3 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
NLRP3 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NLRP3 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NLRP3 protein inhibitors drugs.
NLRP3 protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “NLRP3 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in NLRP3 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
NLRP3 protein inhibitors: Overview
The NLRP3 inflammasome regulates the release of pro-inflammatory cytokines in response to “danger signals,” including the presence of foreign or endogenous molecules that signal infection, tissue damage or metabolic imbalances. Chronic inflammation driven by improper activation of the NLRP3 inflammasome has been implicated in a wide array of diseases, including fibrotic, autoinflammatory and neurodegenerative diseases, as well as certain cancers. Small molecules that selectively inhibit NLRP3 have well-understood potential to address improper activation and treat chronic inflammation at the source, without broadly suppressing the immune system.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence NLRP3 protein inhibitors R&D. The therapies under development are focused on novel approaches for NLRP3 protein inhibitors.
This segment of the NLRP3 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NLRP3 protein inhibitors Emerging Drugs
- SB206: Novan
- NT-0167: Nodthera
Further product details are provided in the report……..
NLRP3 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NLRP3 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on NLRP3 protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
NLRP3 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NLRP3 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NLRP3 protein inhibitors drugs.
NLRP3 protein inhibitors Report Insights
- NLRP3 protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing NLRP3 protein inhibitors drugs?
- How many NLRP3 protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NLRP3 protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NLRP3 protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NLRP3 protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novan
- Novartis
- Nodthera
- Zydus Cadila
- Ventus Therapeutics
- Monte Rosa Therapeutics
- Roche
- Inflazome
- Ionis Pharmaceuticals
- TWi Biotechnology
- SB206
- DFV 890
- NT 0167
- ZYIL-1
- SB 206
- Research programme: NEK7 targetting anti-inflammatories
- Research programme: NLRP3 inflammasome inhibitors
- IZD-334
- Research programme: NLRP3 antisense oligonucleotides
- RG 6418
- Diacerein
- IZD-174
Introduction
Executive Summary
NLRP3 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NLRP3 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
SB206: Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DFV 890: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NT 0167: Nodthera
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: NLRP3 inflammasome inhibitors - Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NLRP3 protein inhibitors Key Companies
NLRP3 protein inhibitors Key Products
NLRP3 protein inhibitors- Unmet Needs
NLRP3 protein inhibitors- Market Drivers and Barriers
NLRP3 protein inhibitors- Future Perspectives and Conclusion
NLRP3 protein inhibitors Analyst Views
NLRP3 protein inhibitors Key Companies
Appendix
Executive Summary
NLRP3 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NLRP3 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
SB206: Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DFV 890: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NT 0167: Nodthera
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: NLRP3 inflammasome inhibitors - Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NLRP3 protein inhibitors Key Companies
NLRP3 protein inhibitors Key Products
NLRP3 protein inhibitors- Unmet Needs
NLRP3 protein inhibitors- Market Drivers and Barriers
NLRP3 protein inhibitors- Future Perspectives and Conclusion
NLRP3 protein inhibitors Analyst Views
NLRP3 protein inhibitors Key Companies
Appendix